[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053377":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":38,"locations":49,"responsibleParty":157,"collaborators":159,"id":162,"slug":163,"hasResults":164,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":164,"sex":170,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":10,"studyType":176,"phases":10,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},{"fullName":5,"class":6},"Centre for Addiction and Mental Health","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"MOT",null,"In the MOT\u002FLight Protocol, clinical, and functional measures will be collected in addition to blood-based 'omics' including proteomic (immune markers) and genomic analysis of DNA derived from blood and\u002For saliva. Over 3 years n=1620 children and youth will be recruited to the MOT\u002FLight Protocol across the CALM Network.\n\nA number of measures will be collected throughout the course of the study in order to capture symptoms across a spectrum of conditions in the target population. Provided that the main objective of the CALM project is to improve clinical care for youth with a particular focus on MMHC, it is vital to use validated standardized assessments that test highly prevalent physical and mental health conditions. MOT\u002FLight measures will be collected via self-report (SR), rated-administered (RA), caregiver-administered (Ca), or a combination",{"label":13,"type":10,"description":14,"interventionNames":10},"Deep Phenotyping","Multidimensional, multilevel data will be obtained in a subcohort of CALM Study youth (3 years n=\\~614) recruited to the MOT who also consent to participate in the Deep Phenotyping protocol. The Deep Phenotyping Protocol includes additional clinical, behavioural, developmental and functional outcomes, not collected as part of the light phenotyping battery as well as the collection of neurocognitive measures and neuroimaging data. Cognitive phenotyping will be administered at 0 and 6 month time points. Neuroimaging will be collected at one time point, harmonized across sites using human connectome quality scanning and to key external initiatives (e.g., neuroimaging via ABCD) facilitating secondary data use, and the utilization of additional cohorts in analysis.",[16,19,22,25,27,30,33,36],{"name":17,"affiliation":5,"role":18},"Louise Gallagher, MB, BCh, PhD","PRINCIPAL_INVESTIGATOR",{"name":20,"affiliation":21,"role":18},"Paul Arnold, MD, PhD","University of Calgary",{"name":23,"affiliation":24,"role":18},"Gary Goldfield, PhD, C. Psych.","The Children's Hospital of Eastern Ontario Research Institute",{"name":26,"affiliation":5,"role":18},"Stephanie Ameis, MD, MSc",{"name":28,"affiliation":29,"role":18},"Suneeta Monga, MD, FRCPC","The Hospital for Sick Children",{"name":31,"affiliation":32,"role":18},"Melissa Kimber, PhD, MSW, RSW","Hamilton Health Sciences Corporation",{"name":34,"affiliation":35,"role":18},"Jennifer Phillips, PhD","The University of Ottawa Institute of Mental Health Research at the Royal",{"name":37,"affiliation":24,"role":18},"Nicole Racine, PhD, C. Psych.",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Louise Gallagher, MD, PhD","CONTACT","416-535-8501","33566","louise.gallagher@camh.ca",{"name":46,"role":41,"phone":47,"phoneExt":10,"email":48},"Janani Selvachandran, PhD","437-441-2294","janani.selvachandran@camh.ca",[50,73,94,114,130,146],{"facility":21,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Calgary","Alberta","T2N 1N4","Canada","CA",{"type":58,"coordinates":59},"Point",[60,61],-114.08529,51.05011,{"lat":61,"lon":60},[64,68,72],{"name":65,"role":41,"phone":66,"phoneExt":10,"email":67},"Paul Arnold, MD, PhD, FRCPC","403-210-6464","paul.arnold@ucalgary.ca",{"name":69,"role":41,"phone":70,"phoneExt":10,"email":71},"Sadanee Pathiranawasam, MSc","647-515-6560","sadanee.pathiranawas@ucalgary.ca",{"name":65,"role":18,"phone":10,"phoneExt":10,"email":10},{"facility":74,"status":51,"city":75,"state":76,"zip":77,"country":55,"countryCode":56,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"McMaster Children's Hospital, Hamilton Health Sciences","Hamilton","Ontario","L8L 2X2",{"type":58,"coordinates":79},[80,81],-79.84963,43.25011,{"lat":81,"lon":80},[84,89,93],{"name":85,"role":41,"phone":86,"phoneExt":87,"email":88},"Melissa Kimber, BA, BSW, MSW, PhD","905-525-9140","27220","kimberms@mcmaster.ca",{"name":90,"role":41,"phone":91,"phoneExt":10,"email":92},"Alexe Bernier, PhD","403-542-5610","bernia1@mcmaster.ca",{"name":85,"role":18,"phone":10,"phoneExt":10,"email":10},{"facility":95,"status":51,"city":96,"state":76,"zip":97,"country":55,"countryCode":56,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Children's Hospital of Eastern Ontario Research Institute","Ottawa","K1H 8L1",{"type":58,"coordinates":99},[100,101],-75.69812,45.41117,{"lat":101,"lon":100},[104,108,112,113],{"name":23,"role":41,"phone":105,"phoneExt":106,"email":107},"613-737-7600","2721","ggoldfield@cheo.on.ca",{"name":109,"role":41,"phone":105,"phoneExt":110,"email":111},"Karina Branje","4899","kbranje@cheo.on.ca",{"name":23,"role":18,"phone":10,"phoneExt":10,"email":10},{"name":37,"role":18,"phone":10,"phoneExt":10,"email":10},{"facility":115,"status":51,"city":96,"state":76,"zip":116,"country":55,"countryCode":56,"cosmosGeoPoint":117,"geoPoint":119,"contacts":120},"The Royal Ottawa Mental Health Centre","K1Z 7K4",{"type":58,"coordinates":118},[100,101],{"lat":101,"lon":100},[121,125,129],{"name":34,"role":41,"phone":122,"phoneExt":123,"email":124},"613-722-6521","6971","jphillips@theroyal.ca",{"name":126,"role":41,"phone":122,"phoneExt":127,"email":128},"Aster Javier, MSc","6437","ajavier@theroyal.ca",{"name":34,"role":18,"phone":10,"phoneExt":10,"email":10},{"facility":29,"status":51,"city":131,"state":76,"zip":132,"country":55,"countryCode":56,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Toronto","M5G 1X8",{"type":58,"coordinates":134},[135,136],-79.39864,43.70643,{"lat":136,"lon":135},[139,142],{"name":28,"role":41,"phone":140,"phoneExt":10,"email":141},"416-813-7531","suneeta.monga@sickkids.ca",{"name":143,"role":41,"phone":144,"phoneExt":10,"email":145},"Atushi Patel","437-212-3207","atushi.patel@sickkids.ca",{"facility":147,"status":51,"city":131,"state":76,"zip":148,"country":55,"countryCode":56,"cosmosGeoPoint":149,"geoPoint":151,"contacts":152},"Centre for Addiction and Mental Health (CAMH)","M6J1H4",{"type":58,"coordinates":150},[135,136],{"lat":136,"lon":135},[153,154,155],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},{"name":46,"role":41,"phone":47,"phoneExt":10,"email":48},{"name":156,"role":18,"phone":10,"phoneExt":10,"email":10},"Stephanie Ameis, MD, MSc, FRCPC",{"type":158,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[160],{"name":161,"class":6},"Ontario Brain Institute","100053377","cohort-network-for-adolescents-and-youth-with-multiple-mental-health-conditions-100053377",false,"NCT07699159","Cohort Network for Adolescents and Youth With multipLe Mental Health Conditions","Cohort Network for Adolescents and Youth With multipLe Mental Health Conditions (CALM): A Master Observational Trial","CALM","Inclusion Criteria:\n\nThe participant must meet all of the inclusion criteria to be eligible for this research study:\n\n* Light Phenotype Eligibility Must sign and date the informed consent form, or provide assent and have a Substitute Decision Maker provide informed consent; Aged 11-24 years old at the time of screening; Any person within age criteria who has previously sought, is seeking, or is accessing mental health services; Are able to complete assessments in English.\n\nDeep Phenotype Eligibility Must be part of the CALM light phenotype cohort; Must sign and date the deep phenotyping informed consent form, or provide assent and have a Substitute Decision Maker provide informed consent.\n\nLight Phenotype Caregiver Participant Eligibility:\n\nAny caregiver of a CALM child\u002Fyouth participant is eligible to participate in the study, insofar as the child\u002Fyouth participant has consented to the light phenotype cohort and has agreed for their caregiver to be contacted to participate in the study; Must sign and date the informed consent form.\n\nDeep Phenotype Caregiver Participant Eligibility:\n\nAny caregiver of a CALM child\u002Fyouth participant is eligible to participate in the study, insofar as the child\u002Fyouth participant has consented to the deep phenotype cohort and has agreed for their caregiver to be contacted to participate in the study; Must sign and date the informed consent form.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this research study:\n\nLight Phenotype Does not provide informed consent (for those with the capacity to consent) or assent (for those who lack the capacity to consent); For those individuals who lack the capacity to consent, the inability of the parent\u002Flegal guardian to provide informed consent for the youth is also an exclusion criterion; Those who lack capacity to consent include individuals who are non-verbal or unable to speak any English.\n\nDeep Phenotype Unable to participate in deep phenotyping protocol (e.g., MRI contraindication, uncorrected vision or hearing impairments that would interfere with data collection, unwillingness to complete assessments); No exclusion criteria are based on race, ethnicity, sex or gender.\n\nLight Phenotype Caregiver Participant Ineligibility:\n\nCaregivers of CALM child\u002Fyouth participants are ineligible to participate in the study if:\n\nThe child\u002Fyouth participant does not agree for their caregiver to be contacted to participate in the study; The child\u002Fyouth participant is not participating in the light phenotype cohort; Does not provide informed consent (for those with the capacity to consent). Those who lack capacity to consent include individuals who are non-verbal or unable to speak any English.\n\nDeep Phenotype Caregiver Participant Ineligibility:\n\nCaregivers of CALM child\u002Fyouth participants are ineligible to participate in the study if:\n\nThe child\u002Fyouth participant does not agree for their caregiver to be contacted to participate in the study; The child\u002Fyouth participant is not participating in the deep phenotype cohort (i.e., is only participating in the light phenotyping cohort); Does not provide informed consent (for those with the capacity to consent). Those who lack capacity to consent include individuals who are non-verbal or unable to speak any English.","ALL","11 Years","24 Years",{"count":174,"type":175},1620,"ESTIMATED","OBSERVATIONAL","The Cohort Network for Adolescents and Youth With multipLe Mental Health Conditions (CALM) Master Observational Trial is a prospective, longitudinal observational study that seeks to improve clinical care for youth with multiple mental health conditions (MMHC), also known as mental health multimorbidity in the literature. MMHC is conceptualized as the presence of two or more mental health diagnoses under the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). MMHC is common in youth seeking mental health services and is associated with less favorable outcomes and greater health services utilization. Mental health disorders also accumulate in youth over time. The Master Observational Trial (MOT) will investigate MMHC in critical developmental periods in youth and identify risk and protective factors that will provide a mechanistic understanding of how MMHC develops over time. A subset of participants will also enroll in a Deep Phenotyping Cohort, which includes enhanced clinical and cognitive assessments and multimodal neuroimaging to investigate neurobiological mechanisms underlying MMHC and identify potential biomarkers of illness complexity and progression.\n\nIn the near future, we aim to add to the current protocol to embed both a clinical trials network for youth mental health in Ontario and Calgary within the CALM study and add digital phenotyping using wearable technology to generate digital and physiological markers of MMHC. The current protocol focuses on establishing the longitudinal MOT cohort and Deep Phenotype Cohort only as a first step towards these long term CALM goals.",[179,180,181],"Multiple Mental Health Conditions","Child Mental Health","Youth Mental Health",[183,184,185,186,187],"multiple mental health conditions","child and youth mental health","mental health multimorbidity","master observational trial","deep phenotyping cohort","2026-07-07",{"date":190,"type":191},"2026-07-13","ACTUAL",{"date":193,"type":191},"2025-03-04",{"date":195,"type":175},"2028-03-31",{"name":5,"class":6},6]